CENTESSA PHARMACEUTICALS-ADR (CNTA) Stock Earnings & Estimates
NASDAQ:CNTA - US1523091007 - ADR
17 USD
-0.01 (-0.06%)
17 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.853M | -100.00% | 15.3M | -100.00% | 141.09M | 422.7M 199.60% | 762.35M 80.35% | 1.151B 50.98% | 1.501B 30.41% | ||||
| EBITDA YoY % growth | -153.6M -1,371.26% | -212.13M -38.11% | -170.19M 19.77% | -175.787M -17.55% | -193.912M 3.07% | -242.346M -24.98% | -281.631M -16.21% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -153.63M -1,371.55% | -212.26M -38.16% | -171M 19.44% | -178.88M -17.54% | -188.447M 6.25% | -231.99M -23.11% | -261.297M -12.63% | -153.051M 41.43% | 69.233M 145.24% | 339.54M 390.43% | 675.72M 99.01% | 994.79M 47.22% | |
| Operating Margin | N/A | N/A | -2,495.26% | N/A | -1,231.68% | N/A | N/A | -108.48% | 16.38% | 44.54% | 58.71% | 66.28% | |
| EPS YoY % growth | N/A | -2.31 -11.38% | -1.57 32.03% | -1.60 -10.19% | -1.41 18.50% | -1.68 -19.29% | -1.79 -6.66% | -0.54 69.86% | 0.88 263.21% | 2.24 154.34% | 4.20 86.97% | 5.77 37.60% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 -5.31% | -0.42 27.72% | -0.42 -110.37% | -0.46 -22.13% | -0.45 -15.18% | -0.47 -11.92% |
| Revenue Q2Q % growth | -100.00% | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -53.913M -17.20% | -56.712M 24.38% | -58.718M -89.41% | -64.566M -17.39% | -60.333M -11.91% | -62.322M -9.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.38 5.00% | -0.35 | -0.03 | -7.99% |
| Q1 2025 Q2Q % growth | -0.20 47.37% | -0.38 | 0.18 | 47.36% |
| Q4 2024 Q2Q % growth | -0.58 -52.63% | -0.46 | -0.12 | -27.41% |
| Q3 2024 Q2Q % growth | -0.37 7.50% | -0.42 | 0.05 | 12.70% |
| Q2 2024 Q2Q % growth | -0.40 -53.85% | -0.39 | -0.01 | -1.54% |
| Q1 2024 Q2Q % growth | -0.38 28.30% | -0.43 | 0.05 | 12.00% |
| Q4 2023 Q2Q % growth | -0.38 15.56% | -0.49 | 0.11 | 22.59% |
| Q3 2023 Q2Q % growth | -0.40 29.82% | -0.53 | 0.13 | 23.96% |
| Q2 2023 Q2Q % growth | -0.26 62.32% | -0.50 | 0.24 | 48.23% |
| Q1 2023 Q2Q % growth | -0.53 11.67% | -0.42 | -0.11 | -25.91% |
| Q4 2022 Q2Q % growth | -0.45 33.82% | -0.49 | 0.04 | 8.28% |
| Q3 2022 Q2Q % growth | -0.57 -26.67% | -0.58 | 0.01 | 1.09% |
| Q2 2022 Q2Q % growth | -0.69 -6.15% | -0.58 | -0.11 | -18.68% |
| Q1 2022 Q2Q % growth | -0.60 19.42% | -0.71 | 0.11 | 15.56% |
| Q4 2021 Q2Q % growth | -0.68 | -0.61 | -0.07 | -11.73% |
| Q3 2021 Q2Q % growth | -0.45 | -0.56 | 0.11 | 20.27% |
| Q2 2021 Q2Q % growth | -0.65 | -0.68 | 0.03 | 4.17% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -7.91% | 12.18% | -6.16% | 5.65% |
| Revenue | N/A | N/A | 10% | N/A |